Efficacy of Vortioxetine on Anhedonia: Results from a Pooled Analysis of Short-Term Studies in Patients with Major Depressive Disorder
Open accessThe DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
PURPOSE: Anhedonia is a core symptom of major depressive disorder (MDD), which has important functional consequences for the patient. This post hoc analysis investigated the relationship between anhedonia and functioning in patients with MDD treated with vortioxetine. PATIENTS AND METHODS: We conducted a pooled analysis of all 11 short-term, double-blind, randomized, placebo-controlled studies of vortioxetine (fixed dose, 5-20 mg/day) in patients with MDD which included Montgomery-Åsberg Depression Rating Scale (MADRS) and Sheehan Disability Scale (SDS) assessments. A short-term, randomized, active-controlled trial of flexible-dose treatment with vortioxetine (10-20 mg/day) versus agomelatine (25-50 mg/day) was also analyzed. Mean changes from baseline to study endpoint in MADRS total, MADRS anhedonia subscale, SDS total, and SDS social-functioning scores were analyzed by a mixed model for repeated measures. The relationship between treatment effects on anhedonia and functioning was investigated using path analysis. RESULTS: A total of 4988 patients with MDD were included in the placebo-controlled studies and 495 in the active-comparator study. Significant dose-dependent improvements in overall depressive symptoms, anhedonia, and measures of functioning were seen in vortioxetine-treated patients compared with those who received placebo or agomelatine. Results of the path analysis for the placebo-controlled studies suggested that the effect on functioning was mostly driven by the effect of treatment on MADRS anhedonia factors. CONCLUSION: Vortioxetine showed significant short-term efficacy against anhedonia in this large population of patients with MDD. In the placebo-controlled studies, improvements in functioning associated with vortioxetine appeared to be mostly driven by the effect of treatment on MADRS anhedonia factors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The mesolimbic dopamine reward circuit in depression
Nestler, E. J., & Carlezon, W. A. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.09.018 · Cited by 2,059
A scale for the assessment of hedonic tone the Snaith-Hamilton pleasure scale
Snaith, R. P., Hamilton, M., Morley, S., Humayan, A., Hargreaves, D., & Trigwell, P. (1995) · British Journal of Psychiatry · doi:10.1192/bjp.167.1.99 · Cited by 1,778
Sheehan, D. V., Harnett-Sheehan, K., & Raj, B. A. (1996) · International Clinical Psychopharmacology · doi:10.1097/00004850-199606003-00015 · Cited by 1,440
Scales for physical and social anhedonia.
Chapman, L. J., Chapman, J. P., & Raulin, M. L. (1976) · Journal of Abnormal Psychology · doi:10.1037/0021-843x.85.4.374 · Cited by 1,234
Dopamine system dysregulation in major depressive disorders
Belujon, P., & Grace, A. A. (2017) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyx056 · Cited by 754
Bauer, M., Pfennig, A., Severus, E., Whybrow, P. C., Angst, J., Möller, H.-J., & Šon behalf of the Task Force on Unipolar Depressive Disorders (2013) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2013.804195 · Cited by 632
Assessing anhedonia in depression: potentials and pitfalls
Rizvi, S. J., Pizzagalli, D. A., Sproule, B. A., & Kennedy, S. H. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.03.004 · Cited by 571
Sanchez, C., Asin, K. E., & Artigas, F. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.07.001 · Cited by 547
McMakin, D. L., Olino, T. M., Porta, G., Dietz, L. J., Emslie, G., Clarke, G., Wagner, K. D., Asarnow, J. R., Ryan, N. D., Birmaher, B., et al. (2012) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2012.01.011 · Cited by 448
Uher, R., Perlis, R. H., Henigsberg, N., Zobel, A., Rietschel, M., Mors, O., Hauser, J., Dernovsek, M. Z., Souery, D., Bajs, M., et al. (2012) · Psychological Medicine · doi:10.1017/s0033291711001905 · Cited by 420
Franken, I. H. A., Rassin, E., & Muris, P. (2007) · Journal of Affective Disorders · doi:10.1016/j.jad.2006.08.020 · Cited by 373
Emotional side-effects of selective serotonin reuptake inhibitors: qualitative study
Price, J., Cole, V., & Goodwin, G. M. (2009) · British Journal of Psychiatry · doi:10.1192/bjp.bp.108.051110 · Cited by 362
Martinotti, G., Sepede, G., Gambi, F., Di Iorio, G., De Berardis, D., Di Nicola, M., Onofrj, M., Janiri, L., & Di Giannantonio, M. (2012) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31825d6c25 · Cited by 276
Mørk, A., Pehrson, A., Brennum, L. T., Nielsen, S. M., Zhong, H., Lassen, A. B., Miller, S., Westrich, L., Boyle, N. J., Sánchez, C., et al. (2012) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.189068 · Cited by 271
Neural correlates of change in major depressive disorder anhedonia following open-label ketamine
Lally, N., Nugent, A. C., Luckenbaugh, D. A., Niciu, M. J., Roiser, J. P., & Zarate, C. A. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114568041 · Cited by 224
Emotional blunting with antidepressant treatments: A survey among depressed patients
Goodwin, G. M., Price, J., De Bodinat, C., & Laredo, J. (2017) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.05.048 · Cited by 202
Vinckier, F., Gourion, D., & Mouchabac, S. (2017) · European Psychiatry · doi:10.1016/j.eurpsy.2017.02.485 · Cited by 201
McIntyre, R., Harrison, J., Loft, H., Jacobson, W., & Olsen, C. (2016) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyw055 · Cited by 185
Self-citationBoulenger, J.-P., Loft, H., & Olsen, C. K. (2014) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000018 · Cited by 176
Self-citationCao, B., Zhu, J., Zuckerman, H., Rosenblat, J. D., Brietzke, E., Pan, Z., Subramanieapillai, M., Park, C., Lee, Y., & McIntyre, R. S. (2019) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2019.01.002 · Cited by 175
Self-citationPehrson, A. L., Cremers, T., Bétry, C., van der Hart, M. G. C., Jørgensen, L., Madsen, M., Haddjeri, N., Ebert, B., & Sanchez, C. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2012.04.006 · Cited by 155
Read, J., Cartwright, C., & Gibson, K. (2014) · Psychiatry Research · doi:10.1016/j.psychres.2014.01.042 · Cited by 150
Henigsberg, N., Mahableshwarkar, A. R., Jacobsen, P., Chen, Y., & Thase, M. E. (2012) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.11m07470 · Cited by 150
Montgomery, S. A., Nielsen, R. Z., Poulsen, L. H., & Häggström, L. (2014) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.2424 · Cited by 143
The efficacy of vortioxetine on anhedonia in patients with major depressive disorder
Cao, B., Park, C., Subramaniapillai, M., Lee, Y., Iacobucci, M., Mansur, R. B., Zuckerman, H., Phan, L., & McIntyre, R. S. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00017 · Cited by 139
Self-citationDimensions in major depressive disorder and their relevance for treatment outcome
Vrieze, E., Demyttenaere, K., Bruffaerts, R., Hermans, D., Pizzagalli, D. A., Sienaert, P., Hompes, T., de Boer, P., Schmidt, M., & Claes, S. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.10.020 · Cited by 138
Jain, R., Mahableshwarkar, A. R., Jacobsen, P. L., Chen, Y., & Thase, M. E. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712000727 · Cited by 132
The Nucleus Accumbens and Ketamine Treatment in Major Depressive Disorder
Abdallah, C. G., Jackowski, A., Salas, R., Gupta, S., Sato, J. R., Mao, X., Coplan, J. D., Shungu, D. C., & Mathew, S. J. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.49 · Cited by 123
Vortioxetine: a novel antidepressant for the treatment of major depressive disorder
Gonda, X., Sharma, S. R., & Tarazi, F. I. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2019.1546691 · Cited by 123
Psychiatric comorbidities in patients with major depressive disorder
Ittasakul, P., Thaipisuttikul, P., Waleeprakhon, P., Wisajun, P., & Jullagate, S. (2014) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s72026 · Cited by 99
Mahableshwarkar, A. R., Jacobsen, P. L., Chen, Y., Serenko, M., & Trivedi, M. H. (2015) · Psychopharmacology · doi:10.1007/s00213-014-3839-0 · Cited by 98
Implications of the DSM's emphasis on sadness and anhedonia in major depressive disorder
Buckner, J. D., Joiner, T. E., Pettit, J. W., Lewinsohn, P. M., & Schmidt, N. B. (2008) · Psychiatry Research · doi:10.1016/j.psychres.2007.05.010 · Cited by 97
Rosenblat, J. D., Simon, G. E., Sachs, G. S., Deetz, I., Doederlein, A., DePeralta, D., Dean, M. M., & McIntyre, R. S. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.09.027 · Cited by 92
Self-citationMahableshwarkar, A. R., Jacobsen, P. L., Serenko, M., Chen, Y., & Trivedi, M. H. (2015) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14m09337 · Cited by 84
IsHak, W. W., Greenberg, J. M., & Cohen, R. M. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.05.048 · Cited by 78
Targeting cytokines in reduction of depressive symptoms: A comprehensive review
Shariq, A. S., Brietzke, E., Rosenblat, J. D., Barendra, V., Pan, Z., & McIntyre, R. S. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2018.01.003 · Cited by 72
Self-citationResidual Symptoms in Depression: Prevalence and Impact
Nierenberg, A. A. (2015) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13097tx1c · Cited by 66
Inoue, T., Sasai, K., Kitagawa, T., Nishimura, A., & Inada, I. (2020) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12956 · Cited by 45
Nishimura, A., Aritomi, Y., Sasai, K., Kitagawa, T., & Mahableshwarkar, A. R. (2018) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12565 · Cited by 45
Reimagining the spectrum of affective disorders
Ng, Q. X., Lim, D. Y., & Chee, K. T. (2020) · Bipolar Disorders · doi:10.1111/bdi.12960 · Cited by 39
Pan, Z., Rosenblat, J. D., Swardfager, W., & McIntyre, R. S. (2017) · Current Pharmaceutical Design · doi:10.2174/1381612823666170111144340 · Cited by 34
Self-citationFischer, A. S., Holt-Gosselin, B., Fleming, S. L., Hack, L. M., Ball, T. M., Schatzberg, A. F., & Williams, L. M. (2021) · Neuropsychopharmacology · doi:10.1038/s41386-020-00905-3 · Cited by 30
Christensen, M. C., Florea, I., Loft, H., & McIntyre, R. S. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.11.074 · Cited by 26
Self-citation
Cited by
Nogo, D., Jasrai, A. K., Kim, H., Nasri, F., Ceban, F., Lui, L. M. W., Rosenblat, J. D., Vinberg, M., Ho, R., & McIntyre, R. S. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06105-9 · Cited by 54
Self-citationChristensen, M. C., Fagiolini, A., Florea, I., Loft, H., Cuomo, A., & Goodwin, G. M. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.07.099 · Cited by 52
Self-citationZheng, W., Gu, L.-M., Zhou, Y.-L., Wang, C.-Y., Lan, X.-F., Zhang, B., Shi, H.-S., Wang, D.-F., & Ning, Y.-P. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.780975 · Cited by 12
Zheng, W., Yang, X.-H., Gu, L.-M., Tan, J.-Q., Zhou, Y.-L., Wang, C.-Y., & Ning, Y.-P. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.06.081 · Cited by 11
Kato, M., Kikuchi, T., Watanabe, K., Sumiyoshi, T., Moriguchi, Y., Åström, D., & Christensen, M. (2023) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s428443 · Cited by 3
“38,39 Just as there is a phenotypic overlap between emotional blunting and anhedonia, there is overlap between the 4 MADRS items identified as important for emotional blunting and those included in the MADRS anhedonia factor score.”
BackgroundSelf-citation
Metadata
- Authors
- McIntyre, R. S., Loft, H., & Christensen, M. C.
- Venue
- Neuropsychiatric Disease and Treatment
- Publisher
- Informa UK Limited
- Published
- 2021-02
- Volume
- Volume 17
- Pages
- 575-585
- ISSN
- 1176-6328 (ISSN-L)
- 1178-2021
- OpenAlex
- W3129382822
- Cited by
- 84
- References
- 43
- FWCI
- 6.75
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.